Get the Stockscreener App
754.45
0.65%
5.115
Regeneron Pharmaceuticals Inc stock is traded at $754.45, with a volume of 361.45K.
It is up +0.65% in the last 24 hours and down -3.22% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$749.33
Open:
$750.34
24h Volume:
361.45K
Relative Volume:
0.37
Market Cap:
$79.24B
Revenue:
$14.25B
Net Income/Loss:
$4.58B
P/E Ratio:
18.06
EPS:
41.7701
Net Cash Flow:
$3.88B
1W Performance:
+1.66%
1M Performance:
-3.22%
6M Performance:
+34.46%
1Y Performance:
+10.91%
1-Day Range:
$747.37
$765.00
1-Week Range:
$718.38
$765.00
52-Week Range:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
753.97 | 78.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.15 | 117.00B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ARGX
Argen X Se Adr
|
823.20 | 50.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
368.49 | 48.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.26 | 37.81B | 4.98B | 69.59M | 525.67M | 0.5197 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-03-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-24-25 | Initiated | HSBC Securities | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $875.00 at Evercore ISI - MarketBeat
REGN: Evercore ISI Group Raises Price Target to $875, Maintains Outperform Rating | REGN Stock News - GuruFocus
Universal Beteiligungs und Servicegesellschaft mbH Increases Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Faces Neurology Leadership Shift As Investors Weigh Pipeline Execution - simplywall.st
Ocular Therapeutix Appoints David W. Robinson as Global Chief Commercial Officer - citybiz
2 Westchester County Teens Among 40 Regeneron Science Talent Search 2026 Finalists - Patch
40 teen scientists vie for $1.8M at Regeneron talent search - Stock Titan
Johnson & Johnson Clears the Patent Cliff as 2026 Guidance Resets the Narrative - Investing.com
58,906 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Rakuten Investment Management Inc. - MarketBeat
Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer - manilatimes.net
Seizert Capital Partners LLC Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
(REGN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Should You Be Excited for Regeneron (REGN)? - Insider Monkey
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Momentum - Yahoo Finance
Allstate Corp Makes New $2.12 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Expansion wave in Saratoga County, New York: Regeneron, GlobalFoundries, Soleno, LISSMAC and more - The Business Journals
Third retinal indication for Eylea 8mg approved in Europe - The Pharma Letter
Sanofi, Regeneron Can't Patent Asthma Prevention Tool - Law360
Neutralizing Antibody Market is Going to Boom, Highlighting - openPR.com
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by ASR Vermogensbeheer N.V. - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Raised by Lmcg Investments LLC - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Evergreen Capital Management LLC - MarketBeat
Howland Capital Management LLC Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Does Regeneron (REGN) Prioritizing In‑House R&D Over Deals Recast Its Long‑Term Risk‑Reward Profile? - simplywall.st
Fjarde AP Fonden Fourth Swedish National Pension Fund Sells 4,200 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron ordered to face lawsuit alleging Medicare fraud over Eylea - MSN
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by PGGM Investments - MarketBeat
Dillon & Associates Inc. Decreases Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Basal Cell Carcinoma Treatment Market to Reach US$ 19.6 Billion - openPR.com
Atopic Dermatitis Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharma, Abbvie, Allergan - Barchart.com
Trading Recap: What are the future prospects of Regeneron Pharmaceuticals IncMarket Growth Report & Weekly Market Pulse Updates - baoquankhu1.vn
Meritage Portfolio Management Buys 9,486 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Nordea Investment Management AB Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Is Regeneron (REGN) Offering Value After Recent Share Price Swings? - Yahoo Finance
JPM26: Regeneron will not overpay in M&A deals amid lead asset patent expiries - Pharmaceutical Technology
This Is What Whales Are Betting On Regeneron Pharmaceuticals - Benzinga
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Regeneron (REGN) and Progyny (PGNY) - The Globe and Mail
Allergic Rhinitis Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Regeneron Pharma, Allergy Therapeutics, Inmunotek, UCB Pharma, Orexo AB, Hyloris Pharma - Barchart.com
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Erasca (ERAS) and Connect Biopharma Holdings (CNTB) - The Globe and Mail
Regeneron's Yancopoulos on Hearing Loss Gene Therapy, Weight Loss Drugs - marketscreener.com
JP Morgan 2026: Regeneron Focusing on Broad Pipeline Development - PharmExec.com
JPM26 Day 1: Obesity Front-and-Center, Q4 Sales Beats - BioSpace
Regeneron Pharmaceuticals (BIT:1REGN) Price Target Increased by 11.61% to 743.10 - Nasdaq
PKO Investment Management Joint Stock Co Trims Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Highlights Growth Strategy and Pipeline at JPM Conference - The Globe and Mail
Regeneron Pharma price target raised to $820 from $800 at Raymond James - Investing.com UK
Market Review: What is the fair value of Regeneron Pharmaceuticals Inc. stock nowBull Run & High Conviction Trade Alerts - Bộ Nội Vụ
Commonwealth Equity Services LLC Cuts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Stop Loss: Will Regeneron Pharmaceuticals Inc. stock split attract more investorsJuly 2025 WrapUp & Safe Swing Trade Setup Alerts - Bộ Nội Vụ
Amgen Fights Regeneron’s Bid to Pause Eylea Antitrust Claims - Bloomberg Law News
Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis: A Strong Buy with 15.19% Return on Equity and 3.53% Potential Upside - DirectorsTalk Interviews
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Regeneron Pharmaceuticals Inc Stock (REGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bassler Bonnie L | Director |
Jan 07 '26 |
Sale |
800.00 |
1,500 |
1,200,000 |
1,703 |
0.79%
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):